TURKU, FINLAND — Even if electrical cardioversion of atrial fibrillation (AF) is carried out without anticoagulation within 48 hours of acute-AF onset, the first 12 hours of that period provide by far ...

Pharmacological- and electrical-first cardioversion worked similarly well for treating acute atrial fibrillation (Afib) in the emergency department, according to the Canadian RAFF2 trial. The 204 ...

ANKARA, TURKEY — A strategy that takes advantage of the C in ICD (implantable cardioverter defibrillator), in which the device delivers a shock aimed at restoring sinus rhythm in patients with atrial ...

Cardioversion is a treatment for a relatively common heart condition called atrial fibrillation. Through this procedure, an abnormally fast or slow heart rate is converted to a normal rhythm with the ...

Introduction: There is insufficient evidence on the efficacy and safety of pharmacological cardioversion of recent-onset atrial fibrillation (AF) in elderly patients. Antazoline has been shown to be ...

Endurance athletes may be at increased risk for lone atrial fibrillation. 1–5 We describe a middle-aged physician athlete with paroxysmal lone atrial fibrillation in whom cardioversion consistently ...

Demonstrating one potential application of the technology, an automated algorithm tied to the KardiaBand wearable ECG (AliveCor) performed “reasonably well” at detecting A-fib in patients scheduled ...

A cardioversion procedure can reset your heart to its normal rhythm. There are two types: Electrical cardioversion. Your doctor gives your heart an electrical shock through paddles or patches on your ...

Cardioversion is commonly performed as part of the rhythm control strategy for symptom and quality of life improvement in symptomatic patients with atrial fibrillation (AF). Better symptom management ...

The conventional treatment strategy for patients with atrial fibrillation who are to undergo electrical cardioversion is to prescribe warfarin for anticoagulation for three weeks before cardioversion.

VANCOUVER, Cardiome Pharma Corp. today announced that an independent study conducted by investigators at the University of Leipzig Heart Center,Germany, found that intravenous vernakalant facilitated ...